Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Next Previous
Trial Profile

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-756
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 01 Feb 2025 Results(From 27 December 2018 to 5 August 2022, n=1278,data cutoff, 25 May 2023) discussing significance of addition of pembrolizumab to neoadjuvant chemotherapy with respect to pathological complete response rate in patients with high-risk, early-stage ER+/HER2 breast cancer, published in the Nature Medicine
  • 22 Mar 2024 Results of primary pCR results and residual cancer burden (RCB) outcomes, presented at the 14th European Breast Cancer Conference
  • 09 Dec 2023 Results assessing primary pCR results and residual cancer burden (RCB) outcomes presented at the 46th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top